Hims & Hers Shares Soar 40% on Reported Novo Nordisk Deal for Weight-Loss Drugs
HIMS sits 63% above its 52-week low of $13.74.
Summary
Hims & Hers Health is reportedly nearing a deal with Novo Nordisk to offer weight-loss drugs on its platform, resolving a prior dispute and sending HIMS shares up 40% in pre-market trading. This development, initially reported by Bloomberg, signifies a major strategic shift. The news follows Hims & Hers' recent re-entry into the compounded GLP-1 market via a pharmacy partner, highlighting its commitment to the weight-loss sector. A formal partnership with Novo Nordisk, a leader in FDA-approved GLP-1 medications, would significantly enhance Hims & Hers' credibility and market position, removing a key competitive overhang. Investors will now await official confirmation and the specific terms of the agreement.
At the time of this announcement, HIMS was trading at $22.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: ShareCast.